KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial.

Lars L Raket, Ming Lu, Cynthia D Evans, Jennifer A Zimmer, JonDavid Sparks, Emily C Collins, Sergey Shcherbinin, Hong Wang, Emel Serap Monkul Nery, Stéphane Epelbaum, Grazia Dell'Agnello, Dawn A Brooks, John R Sims, Mark A Mintun

Alzheimers Dement 22(6) e71577

PMID42273802
PMCIDPMC13254682
DOI10.1002/alz.71577
发表日期2026-06-11
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。
摘要

摘要

INTRODUCTION: Clinical trials indicate that disease-modifying therapies can slow clinical decline in Alzheimer's disease (AD), with earlier initiation associated with greater slowing. METHODS: In the TRAILBLAZER-ALZ 2 trial, the treatment effect of donanemab on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score was assessed across disease stages defined by baseline tau PET, plasma P-tau217 levels, or predicted disease progression. RESULTS: Donanemab-mediated slowing of disease progression occurred across baseline tau PET and plasma P-tau217 levels. Participants with lower baseline tau PET and P-tau217 showed greater slowing with donanemab versus placebo. Modeling CDR-SB scores indicated that earlier treatment (at the 25th percentile of baseline Predicted disease progression) delayed disease progression by 60% over 76 weeks, compared to 33% and 17% at the 50th and 75th percentiles. DISCUSSION: Donanemab benefited participants with early symptomatic AD across clinical and pathological severities, with the greatest slowing in those treated earlier. CLINICALTRIALS: gov Identifier: NCT04437511.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Clinical efficacy estimated across levels of tau: Earlier stage of disease defined by tau biomarkers shows larger donanemab treatment effects compared to placebo. (A) Clinical efficacy estimated across levels of tau. Tau PET categories at baseline: 1.00: anchor point representing no tau; 1.04: historical level of αβ positive, deemed visually tau negative; 1.21: mean in TRAILBLAZER‐ALZ 2 low–medium tau population; 1.35: mean in TRAILBLAZER‐ALZ 2 combined population; 1.69: mean in TRAILBLAZER‐ALZ 2 high tau population; 2.00: anchor point representing very high tau level. The Y‐ axis denotes the percentage slowing of CDR‐SB at 76 weeks. (B) CDR‐SB baseline P‐tau217 terciles. Number of participants are represented within the bars. Adjusted change from baseline, SE, and p‐values are derived using a mixed‐effects model using the natural cubic spline with two degrees of freedom methodology that was prespecified for primary efficacy analyses but including an adjustment term modeling tercile group‐by‐basis expansion term‐by‐treatment interaction. TRAILBLAZER‐ALZ 2 combined population. p ‐Values are nominal. CDR‐SB, Clinical Dementia Rating Scale Sum of Boxes; SE, standard error.
非 KM Figure
FIGURE 2Estimated stage‐dependent treatment effects over 76‐week treatment period. A latent‐time mixed‐effects model was fitted on longitudinal trajectories of CDR‐SB scores, staging participants relative to each other on a predicted disease progression time scale. The treatment effect of donanemab was modeled as proportional time saving (green solid lines), depending on a participant's baseline predicted disease progression. This allows exploration of donanemab efficacy when initiating treatment at different times along the predicted disease progression timeline. The baseline distribution of predicted disease progression is shown in histogram (light blue), and the estimated effect of treatment initiation is illustrated at the 25 th , 50 th , and 75 th percentiles of the baseline predicted disease progression distribution. CDR‐SB, Clinical Dementia Rating Scale Sum of Boxes.
非 KM Figure
FIGURE 3Modeling long‐term benefit of donanemab and delay to severe dementia. Long‐term trajectories of donanemab‐mediated delays (green dashed lines) of severe dementia (defined as CDR‐SB = 16) versus the placebo‐equivalent predicted disease progression (solid gray line) were extrapolated using a latent‐time disease progression model of CDR‐SB scores. The estimated effects of treatment initiation at the 25 th , 50 th , or 75 th percentiles of the baseline predicted disease progression distribution are illustrated. This extrapolation scenario corresponds to a fading‐slowing scenario where the time savings estimate is updated every 76 weeks since baseline, based on placebo‐equivalent predicted disease progression reached after every 76‐week period. CDR‐SB, Clinical Dementia Rating Scale Sum of Boxes.
非 KM Figure